美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Tvardi Therapeutics Inc

17.04

-1.2095-6.63%

盤後：16.15-0.8891-5.22%16:54 EDT

成交量：3.82萬

成交額：65.28萬

市值：1.59億

市盈率：-1.10

高：19.80

開：17.96

低：15.13

收：18.25

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Tvardi Therapeutics Inc

交易所：

NASDAQ

成立時間：

2017

員工人數：

- -

公司地址：

3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States

官網：

http://tvarditherapeutics.com

郵編：

77478

電話：

傳真：

- -

簡介：

Tvardi Therapeutics, Inc.於2017年12月20日註冊成立，是一家總部位於德克薩斯州休斯頓的特拉華州公司。該公司是一家臨床階段的生物製藥公司，專註於開發針對STAT3的新型口服小分子療法，以治療具有重大未滿足需求的纖維化驅動疾病。基於其創始人的開創性工作和對轉錄因子STAT3的深刻理解，該公司設計了一種創新方法來直接抑制STAT3，這是一種經過高度驗證但在歷史上是不可藥物的靶點。利用這些專業知識，該公司正在開發具有差異化作用機制和方便的口服給藥的STAT3抑製劑管道。該公司的主要候選產品TTI-101目前處於2期臨床開發階段，用於治療纖維化驅動的疾病，初步重點是特發性肺纖維化、IPF和肝細胞癌、HCC。

董事

名稱

職位

Derek Chalmers

Director,President and Chief Executive Officer

Dean Slagel

董事

Harrison M. Bains, Jr.

董事

Jeffrey L. Ives

董事

Martin Vogelbaum

董事

股東

名稱

職位

Derek Chalmers

Director,President and Chief Executive Officer

Josef Schoell

Treasurer, Chief Financial Officer

Frederique Menzaghi

Vice President - Research and Development

Joseph Stauffer

Chief Medical Officer

Michael E. Lewis

Chief Scientific Advisor

Scott M. Terrillion

General Counsel, Secretary

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/TVRD/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":17.0391,"timestamp":1744920000000,"preClose":18.2486,"halted":0,"volume":38248,"hourTrading":{"tag":"盘后","latestPrice":16.15,"preClose":17.0391,"latestTime":"16:54 EDT","volume":316,"amount":5106.8,"timestamp":1744923247847},"delay":0,"floatShares":3316400,"shares":9355542,"eps":-15.531682,"marketStatus":"休市中","change":-1.2095,"latestTime":"04-17 16:00:00 EDT","open":17.96,"high":19.8,"low":15.1301,"amount":652804.509896,"amplitude":0.255905,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-15.531682,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":18.2486,"preHourTrading":{"tag":"盘前","latestPrice":15.5,"preClose":18.06,"latestTime":"09:24 EDT","volume":267,"amount":4501.361543999999,"timestamp":1744896279023},"postHourTrading":{"tag":"盘后","latestPrice":16.15,"preClose":17.0391,"latestTime":"16:54 EDT","volume":316,"amount":5106.8,"timestamp":1744923247847},"volumeRatio":1.1665172183900896},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":3316400,"roa":"--","roe":"--","lyrEps":-15.531682,"volumeRatio":1.1665172183900896,"shares":9355542,"dividePrice":0,"high":19.8,"amplitude":0.255905,"preClose":18.2486,"low":15.1301,"week52Low":8.1252,"pbRate":"--","week52High":31.32,"institutionHeld":0,"latestPrice":17.0391,"eps":-15.531682,"divideRate":0,"volume":38248,"delay":0,"ttmEps":-15.531682,"open":17.96,"prevYearClose":18.36,"prevWeekClose":14.7,"prevMonthClose":15.21,"prevQuarterClose":15.21,"fiveDayClose":14.595,"twentyDayClose":15.45,"sixtyDayClose":14.34},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":570288312,"yearFounded":2017,"address":"3 Sugar Creek Center Boulevard,Suite 525,Sugar Land,Texas,United States","zipCode":"77478","officePhone":"832-413-1362"},"stockCompanyDetail":{"websiteUrl":"http://tvarditherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1675},{"period":"1month","weight":0.0923},{"period":"3month","weight":0.2214},{"period":"6month","weight":0.7854},{"period":"1year","weight":-0.3533},{"period":"ytd","weight":-0.0719}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Tvardi Therapeutics, Inc.於2017年12月20日註冊成立，是一家總部位於德克薩斯州休斯頓的特拉華州公司。該公司是一家臨床階段的生物製藥公司，專註於開發針對STAT3的新型口服小分子療法，以治療具有重大未滿足需求的纖維化驅動疾病。基於其創始人的開創性工作和對轉錄因子STAT3的深刻理解，該公司設計了一種創新方法來直接抑制STAT3，這是一種經過高度驗證但在歷史上是不可藥物的靶點。利用這些專業知識，該公司正在開發具有差異化作用機制和方便的口服給藥的STAT3抑製劑管道。該公司的主要候選產品TTI-101目前處於2期臨床開發階段，用於治療纖維化驅動的疾病，初步重點是特發性肺纖維化、IPF和肝細胞癌、HCC。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.042039},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019771},{"month":3,"riseRate":0.583333,"avgChangeRate":0.021822},{"month":4,"riseRate":0.25,"avgChangeRate":-0.091823},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.001774},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.002947},{"month":7,"riseRate":0.454545,"avgChangeRate":0.089214},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.002014},{"month":9,"riseRate":0.181818,"avgChangeRate":-0.067808},{"month":10,"riseRate":0.545455,"avgChangeRate":-0.031996},{"month":11,"riseRate":0.545455,"avgChangeRate":0.051738},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.02182}],"exchange":"NASDAQ","name":"Tvardi Therapeutics Inc","nameEN":"Tvardi Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":{"directors":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Dean Slagel","position":"董事"},{"name":"Harrison M. Bains, Jr.","position":"董事"},{"name":"Jeffrey L. Ives","position":"董事"},{"name":"Martin Vogelbaum","position":"董事"}],"executives":[{"name":"Derek Chalmers","position":"Director,President and Chief Executive Officer"},{"name":"Josef Schoell","position":"Treasurer, Chief Financial Officer"},{"name":"Frederique Menzaghi","position":"Vice President - Research and Development"},{"name":"Joseph Stauffer","position":"Chief Medical Officer"},{"name":"Michael E. Lewis","position":"Chief Scientific Advisor"},{"name":"Scott M. Terrillion","position":"General Counsel, Secretary"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-12-31","symbol":"TVRD","defaultRemindTime":1735655400000,"type":"split","dateTimestamp":1735621200000,"forFactor":12,"toFactor":1,"ratio":12},{"market":"US","date":"2024-11-14","symbol":"TVRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2024-08-14","symbol":"TVRD","fiscalQuarterEnding":"2024/06","expectedEps":-0.29,"name":null,"time":"盤後","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{}}}